Navigation Links
Are we cherry picking participants for studies of antidepressants?
Date:4/28/2009

PITTSBURGH, April 28 Findings from clinical studies used to gain Food and Drug Administration approval of common antidepressants are not applicable to most patients with depression, according to a report led by the University of Pittsburgh Graduate School of Public Health. Published in the May issue of the American Journal of Psychiatry, the study suggests only a small percentage of people with depression qualify for these studies, and those who do not qualify are often treated with the same medications but may suffer poorer clinical outcomes.

A part of the National Institute of Mental Health-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project the largest study of the treatment of depression conducted in the United States researchers compared symptoms and outcomes in depressed patients who met phase III study inclusion criteria to those who did not. Phase III studies for antidepressants determine the effectiveness of the drug in comparison to a placebo. The inclusion criteria for these studies are not standardized nor subject to federal guidelines, resulting in some variation from study to study in the profile of eligible patients. Typically excluded are patients with milder forms of depression, who might be more likely to respond to a placebo drug, and those who may have chronic depression or psychiatric and medical co-morbidities additional illnesses or conditions.

After assessing 2,855 patients treated with citalopram, a commonly prescribed selective serotonin reuptake inhibitor for mood disorders, study authors concluded that fewer than one in four, or 22.2 percent, of the patients met the usual criteria for inclusion in phase III antidepressant trials.

"Only a small percentage of depressed patients in our study would have qualified for inclusion in phase III efficacy trials of depression drugs," said study lead author, Stephen Wisniewski, Ph.D., professor of epidemiology and co-director of the Epidemiology Data Center, University of Pittsburgh Graduate School of Public Health. "This raises major concerns about whether results from traditional phase III studies can be generalized to most people with depression, who also often suffer from anxiety, substance abuse and other medical and psychiatric problems."

When Dr. Wisniewski and colleagues further assessed how well patients did on treatment, they found that those who met the eligibility criteria for phase III trials had better outcomes, including higher remission rates, less severe side effects and serious adverse events. The depression remission rate in the patients who met the criteria was 34.4 percent, compared to only 24.7 percent in the ineligible group. Additionally, the drug response rate also was higher in the eligible group 51.6 percent compared to 39.1 percent of the ineligible group.

"Results from research studies suggest more optimistic outcomes than may exist for real-world patients receiving treatment for depression," said Dr. Wisniewski. Although phase III eligibility criteria could be changed to include a broader population of patients, Dr. Wisniewski cautions that this could come at the cost of more serious side effects in patients who have co-morbidities and are generally sicker. These patients may not be able to safely tolerate the drugs being tested. Instead, he suggests medical care providers who treat patients with depression use their professional judgment by noting that most phase III findings are based on patients who may be very different than those under their care.


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Cherrybrook Kitchen Announces New Partnership With Arthur
2. Credit Union Cherry Blossom Ten Mile Run Cherry Blossom Ten-Miler Raises $400,000 For Children's National Medical Center
3. 7UP Gives Consumers a New Reason to Fall in Love - New Cherry 7UP Antioxidant
4. Cherry-Enriched Diet Cut Heart Risks in Rats
5. Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services
6. Reported Health Benefits of Tart Cherry Boosts Juice Distribution in Southern U.S.
7. Hoffa, Cherry to Speak at Community Rally Supporting Genesys Nurses
8. Sleep Medicine Associates Opens New Doors at Swedish - Cherry Hill Campus
9. Picking the Right Toys Isnt Childs Play
10. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
11. Innovation and Strategic Alliances Come to the Rescue of Participants in Mature Brazilian Market for Food Emulsifiers, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the ... , “There were things that his parents and teachers had asked of him that he ... he was going to defy the Almighty Creator. There were some who would have felt ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Bruce Trimble ... without requiring a referral. Trimble Dental offers a variety of services to ... dental implants. Whether patients have discolored, crooked or missing teeth in Eau Claire, ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the second major ... in 2014. It is the culmination of collaborative efforts by members of ... OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided key technical ...
(Date:3/27/2017)... Boston, MA (PRWEB) , ... March 27, 2017 ... ... NEJM Group, the organization behind the New England Journal of Medicine and NEJM ... , NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017  BERG, a biopharmaceutical company uncovering ... approach, today announced that the company,s Interrogative ... new data using a cold-induced model to ... Joslin Diabetes Center led the investigation with ... analysis of samples.  The findings were published ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... mixed colors as the NASDAQ Composite closed the trading ... 0.29% lower; and the S&P 500 was down 0.08%. ... of nine sectors finishing the day in green. Pre-market ... stocks: Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: